Motley Fool
- Home
- CRSP
as of 03-20-2026 3:55pm EST
$46.25
$0.70
-1.49%
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
| Founded: | 2013 | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 4.7B | IPO Year: | 2016 |
| Target Price: | $70.29 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.47 | EPS Growth: | -49.08 |
| 52 Week Low/High: | $30.06 - $78.48 | Next Earning Date: | 05-05-2026 |
| Revenue: | $289,590,000 | Revenue Growth: | 9169.85% |
| Revenue Growth (this year): | 1082.59% | Revenue Growth (next year): | 87.74% |
| P/E Ratio: | -7.26 | Index: | N/A |
| Free Cash Flow: | -345928000.0 | FCF Growth: | N/A |
AI-Powered CRSP Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 72.73%
72.73%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of CRISPR Therapeutics AG (CRSP)
Kulkarni Samarth
Sell
Chief Executive Officer
CRSP Mar 16, 2026
Avg Cost/Share
$48.26
Shares
10,349
Total Value
$499,442.74
Owned After
245,834
SEC Form 4
KASINGER JAMES R.
Sell
General Counsel and Secretary
CRSP Mar 16, 2026
Avg Cost/Share
$48.26
Shares
3,450
Total Value
$166,497.00
Owned After
91,240
SEC Form 4
Prasad Raju
Sell
Chief Financial Officer
CRSP Mar 16, 2026
Avg Cost/Share
$48.26
Shares
9,869
Total Value
$476,277.94
Owned After
17,794
Patel Naimish
Sell
Chief Medical Officer
CRSP Mar 16, 2026
Avg Cost/Share
$48.26
Shares
3,150
Total Value
$152,019.00
Owned After
13,143
SEC Form 4
Kulkarni Samarth
Sell
Chief Executive Officer
CRSP Mar 11, 2026
Avg Cost/Share
$52.80
Shares
9,798
Total Value
$517,334.40
Owned After
245,834
SEC Form 4
KASINGER JAMES R.
Sell
General Counsel and Secretary
CRSP Mar 11, 2026
Avg Cost/Share
$52.80
Shares
2,800
Total Value
$147,840.00
Owned After
91,240
SEC Form 4
Kulkarni Samarth
Sell
Chief Executive Officer
CRSP Feb 19, 2026
Avg Cost/Share
$52.58
Shares
6,967
Total Value
$366,324.86
Owned After
245,834
SEC Form 4
KASINGER JAMES R.
Sell
General Counsel and Secretary
CRSP Feb 19, 2026
Avg Cost/Share
$52.58
Shares
2,112
Total Value
$111,048.96
Owned After
91,240
SEC Form 4
Kulkarni Samarth
Sell
Chief Executive Officer
CRSP Jan 22, 2026
Avg Cost/Share
$60.23
Shares
60,000
Total Value
$3,613,800.00
Owned After
245,834
SEC Form 4
Prasad Raju
Sell
Chief Financial Officer
CRSP Jan 22, 2026
Avg Cost/Share
$60.19
Shares
34,972
Total Value
$2,104,964.68
Owned After
17,794
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Kulkarni Samarth | CRSP | Chief Executive Officer | Mar 16, 2026 | Sell | $48.26 | 10,349 | $499,442.74 | 245,834 | |
| KASINGER JAMES R. | CRSP | General Counsel and Secretary | Mar 16, 2026 | Sell | $48.26 | 3,450 | $166,497.00 | 91,240 | |
| Prasad Raju | CRSP | Chief Financial Officer | Mar 16, 2026 | Sell | $48.26 | 9,869 | $476,277.94 | 17,794 | |
| Patel Naimish | CRSP | Chief Medical Officer | Mar 16, 2026 | Sell | $48.26 | 3,150 | $152,019.00 | 13,143 | |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Mar 11, 2026 | Sell | $52.80 | 9,798 | $517,334.40 | 245,834 | |
| KASINGER JAMES R. | CRSP | General Counsel and Secretary | Mar 11, 2026 | Sell | $52.80 | 2,800 | $147,840.00 | 91,240 | |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Feb 19, 2026 | Sell | $52.58 | 6,967 | $366,324.86 | 245,834 | |
| KASINGER JAMES R. | CRSP | General Counsel and Secretary | Feb 19, 2026 | Sell | $52.58 | 2,112 | $111,048.96 | 91,240 | |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Jan 22, 2026 | Sell | $60.23 | 60,000 | $3,613,800.00 | 245,834 | |
| Prasad Raju | CRSP | Chief Financial Officer | Jan 22, 2026 | Sell | $60.19 | 34,972 | $2,104,964.68 | 17,794 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 12, 2026 · 100% conf.
AI Prediction BUY
1D
+5.73%
$51.74
Act: +8.46%
5D
+9.45%
$53.56
Act: +9.26%
20D
+10.47%
$54.06
Price: $48.93 Prob +5D: 100% AUC: 1.000
0001193125-26-048873
8-K
0001674416false00-000000000016744162026-02-122026-02-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 12, 2026
CRISPR THERAPEUTICS AG
(Exact name of registrant as specified in its charter)
Switzerland
001-37923
Not Applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Baarerstrasse 14
6300 Zug, Switzerland
Not Applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: 41 (0)41 561 32 77
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Shares, nominal value CHF 0.03
CRSP
The NASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 12, 2026, CRISPR Therapeutics AG announced its financial results for the quarter and year ended December 31, 2025 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed:
Exhibit No.
Description
99.1
Press Release by CRISPR Therapeutics AG, dated February 12, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CRISPR Therapeutics AG
Date:
February 12, 2026
By:
/s/ Samarth Kulkarni
Samarth Kulkarni, Ph.D. Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 10, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 10, 2025
0001193125-25-273329
8-K
0001674416false00-000000000016744162025-11-102025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 10, 2025
CRISPR THERAPEUTICS AG
(Exact name of registrant as specified in its charter)
Switzerland
001-37923
Not Applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Baarerstrasse 14
6300 Zug, Switzerland
Not Applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: 41 (0)41 561 32 77
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Shares, nominal value CHF 0.03
CRSP
The NASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 10, 2025, CRISPR Therapeutics AG announced its financial results for the quarter ended September 30, 2025 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed:
Exhibit No.
Description
99.1
Press Release by CRISPR Therapeutics AG, dated November 10, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CRISPR Therapeutics AG
Date:
November 10, 2025
By:
/s/ Samarth Kulkarni
Samarth Kulkarni, Ph.D. Chief Executive Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 4, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 4, 2025
0000950170-25-102027
8-K
0001674416false00-000000000016744162025-08-042025-08-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 4, 2025
CRISPR THERAPEUTICS AG
(Exact name of registrant as specified in its charter)
Switzerland
001-37923
Not Applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Baarerstrasse 14
6300 Zug, Switzerland
Not Applicable
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: 41 (0)41 561 32 77
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Shares, nominal value CHF 0.03
CRSP
The NASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 4, 2025, CRISPR Therapeutics AG announced its financial results for the quarter ended June 30, 2025 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed:
Exhibit No.
Description
99.1
Press Release by CRISPR Therapeutics AG, dated August 4, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CRISPR Therapeutics AG
Date:
August 4, 2025
By:
/s/ Samarth Kulkarni
Samarth Kulkarni, Ph.D. Chief Executive Officer
Latest CRISPR Therapeutics AG News
CRSP Breaking Stock News: Dive into CRSP Ticker-Specific Updates for Smart Investing
Zacks
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
➖
AI Sentiment
Neutral
4/10
Insider Monkey
Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now?
📈
AI Sentiment
Highly Positive
9/10
Compare CRSP vs Leading Stocks
See how CRSP stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CRSP CRISPR Therapeutics AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.